NKGen Biotech (NKGN) Competitors

$0.06 0.00 (0.00%)

As of 05/1/2026 10:09 AM Eastern

NKGN vs. PLRZ, SNTI, BCTX, AIXC, and BGM

Should you be buying NKGen Biotech stock or one of its competitors? The main competitors of NKGen Biotech include Polyrizon (PLRZ), Senti Biosciences (SNTI), Briacell Therap (BCTX), Qualigen Therapeutics (AIXC), and BGM Group (BGM). These companies are all part of the "pharmaceutical products" industry.

How does NKGen Biotech compare to Polyrizon?

Polyrizon (NASDAQ:PLRZ) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

: In the previous week, Polyrizon had 4 more articles in the media than NKGen Biotech. MarketBeat recorded 4 mentions for Polyrizon and 0 mentions for NKGen Biotech. Polyrizon's average media sentiment score of 0.18 beat NKGen Biotech's score of 0.00 indicating that Polyrizon is being referred to more favorably in the media.
Company Overall Sentiment
Polyrizon Neutral
NKGen Biotech Neutral
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Polyrizon N/A N/A -$3.34M N/A N/A
NKGen Biotech N/A N/A -$82.94M -$1.51 N/A
: Company Net Margins Return on Equity Return on Assets
Polyrizon N/A N/A N/A
NKGen Biotech N/A N/A -479.36%
: Polyrizon has a beta of -2.04, indicating that its stock price is 304% less volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500.
: 76.2% of NKGen Biotech shares are owned by institutional investors. 10.4% of NKGen Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Polyrizon
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
NKGen Biotech
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00

Company	Overall Sentiment
Polyrizon	Neutral
NKGen Biotech	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
NKGen Biotech	N/A	N/A	-$82.94M	-$1.51	N/A

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
NKGen Biotech	N/A	N/A	-479.36%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NKGen Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Polyrizon beats NKGen Biotech on 5 of the 8 factors compared between the two stocks.

How does NKGen Biotech compare to Senti Biosciences?

Senti Biosciences (NASDAQ:SNTI) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

: Senti Biosciences has higher revenue and earnings than NKGen Biotech. Senti Biosciences is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Senti Biosciences $20K 1,485.38 -$61.44M -$3.19 N/A
NKGen Biotech N/A N/A -$82.94M -$1.51 N/A
: 25.7% of Senti Biosciences shares are owned by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are owned by institutional investors. 3.1% of Senti Biosciences shares are owned by insiders. Comparatively, 10.4% of NKGen Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
: In the previous week, Senti Biosciences had 1 more articles in the media than NKGen Biotech. MarketBeat recorded 1 mentions for Senti Biosciences and 0 mentions for NKGen Biotech. Senti Biosciences' average media sentiment score of 0.00 equaled NKGen Biotech'saverage media sentiment score.
Company Overall Sentiment
Senti Biosciences Neutral
NKGen Biotech Neutral
: NKGen Biotech's return on equity of 0.00% beat Senti Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Senti Biosciences N/A -301.48% -90.03%
NKGen Biotech N/A N/A -479.36%
: Senti Biosciences currently has a consensus target price of $8.50, suggesting a potential upside of 790.99%. Given Senti Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Senti Biosciences is more favorable than NKGen Biotech.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Senti Biosciences
1 Sell rating(s)
0 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
2.80
NKGen Biotech
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Senti Biosciences has a beta of 2.09, suggesting that its stock price is 109% more volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$20K	1,485.38	-$61.44M	-$3.19	N/A
NKGen Biotech	N/A	N/A	-$82.94M	-$1.51	N/A

Company	Overall Sentiment
Senti Biosciences	Neutral
NKGen Biotech	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-301.48%	-90.03%
NKGen Biotech	N/A	N/A	-479.36%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
NKGen Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Senti Biosciences beats NKGen Biotech on 9 of the 14 factors compared between the two stocks.

How does NKGen Biotech compare to Briacell Therap?

NKGen Biotech (NYSE:NKGN) and Briacell Therap (NASDAQ:BCTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

: In the previous week, NKGen Biotech's average media sentiment score of 0.00 equaled Briacell Therap'saverage media sentiment score.
Company Overall Sentiment
NKGen Biotech Neutral
Briacell Therap Neutral
: 76.2% of NKGen Biotech shares are owned by institutional investors. Comparatively, 15.4% of Briacell Therap shares are owned by institutional investors. 10.4% of NKGen Biotech shares are owned by insiders. Comparatively, 0.7% of Briacell Therap shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
: NKGen Biotech has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, Briacell Therap has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.
: NKGen Biotech's return on equity of 0.00% beat Briacell Therap's return on equity.
Company Net Margins Return on Equity Return on Assets
NKGen Biotech N/A N/A -479.36%
Briacell Therap N/A -173.08% -139.64%
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NKGen Biotech
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Briacell Therap
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: Briacell Therap is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NKGen Biotech N/A N/A -$82.94M -$1.51 N/A
Briacell Therap N/A N/A -$26.31M -$23.33 N/A

Company	Overall Sentiment
NKGen Biotech	Neutral
Briacell Therap	Neutral

Company	Net Margins	Return on Equity	Return on Assets
NKGen Biotech	N/A	N/A	-479.36%
Briacell Therap	N/A	-173.08%	-139.64%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NKGen Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NKGen Biotech	N/A	N/A	-$82.94M	-$1.51	N/A
Briacell Therap	N/A	N/A	-$26.31M	-$23.33	N/A

Summary

NKGen Biotech beats Briacell Therap on 5 of the 9 factors compared between the two stocks.

How does NKGen Biotech compare to Qualigen Therapeutics?

Qualigen Therapeutics (NASDAQ:AIXC) and NKGen Biotech (NYSE:NKGN) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

: In the previous week, Qualigen Therapeutics had 2 more articles in the media than NKGen Biotech. MarketBeat recorded 2 mentions for Qualigen Therapeutics and 0 mentions for NKGen Biotech. Qualigen Therapeutics' average media sentiment score of 0.00 equaled NKGen Biotech'saverage media sentiment score.
Company Overall Sentiment
Qualigen Therapeutics Neutral
NKGen Biotech Neutral
: 3.2% of Qualigen Therapeutics shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 1.2% of Qualigen Therapeutics shares are held by insiders. Comparatively, 10.4% of NKGen Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: Qualigen Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500.
: Company Net Margins Return on Equity Return on Assets
Qualigen Therapeutics N/A N/A -83.21%
NKGen Biotech N/A N/A -479.36%
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qualigen Therapeutics
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
NKGen Biotech
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Qualigen Therapeutics is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Qualigen Therapeutics N/A N/A -$16.97M -$7.50 N/A
NKGen Biotech N/A N/A -$82.94M -$1.51 N/A

Company	Overall Sentiment
Qualigen Therapeutics	Neutral
NKGen Biotech	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	N/A	-83.21%
NKGen Biotech	N/A	N/A	-479.36%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NKGen Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$7.50	N/A
NKGen Biotech	N/A	N/A	-$82.94M	-$1.51	N/A

Summary

NKGen Biotech beats Qualigen Therapeutics on 5 of the 9 factors compared between the two stocks.

How does NKGen Biotech compare to BGM Group?

NKGen Biotech (NYSE:NKGN) and BGM Group (NASDAQ:BGM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NKGen Biotech
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
BGM Group
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: BGM Group has higher revenue and earnings than NKGen Biotech.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NKGen Biotech N/A N/A -$82.94M -$1.51 N/A
BGM Group $25.10M 1.14 -$1.44M N/A N/A
: In the previous week, NKGen Biotech's average media sentiment score of 0.00 equaled BGM Group'saverage media sentiment score.
Company Overall Sentiment
NKGen Biotech Neutral
BGM Group Neutral
: NKGen Biotech has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, BGM Group has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500.
: 76.2% of NKGen Biotech shares are held by institutional investors. 10.4% of NKGen Biotech shares are held by insiders. Comparatively, 58.7% of BGM Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
: Company Net Margins Return on Equity Return on Assets
NKGen Biotech N/A N/A -479.36%
BGM Group N/A N/A N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NKGen Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NKGen Biotech	N/A	N/A	-$82.94M	-$1.51	N/A
BGM Group	$25.10M	1.14	-$1.44M	N/A	N/A

Company	Overall Sentiment
NKGen Biotech	Neutral
BGM Group	Neutral

Company	Net Margins	Return on Equity	Return on Assets
NKGen Biotech	N/A	N/A	-479.36%
BGM Group	N/A	N/A	N/A

Summary

BGM Group beats NKGen Biotech on 6 of the 7 factors compared between the two stocks.

Get NKGen Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NKGN vs. The Competition

Export

Metric	NKGen Biotech	Biological Products Industry	Medical Sector	NYSE Exchange
Market Cap	$7.84M	$328.15M	$6.25B	$22.95B
Dividend Yield	N/A	N/A	2.73%	4.03%
P/E Ratio	-0.01	N/A	29.04	28.58
Price / Sales	N/A	189.48	476.61	23.58
Price / Cash	N/A	22.44	27.62	19.03
Price / Book	-0.02	4.73	9.67	4.68
Net Income	-$82.94M	-$132.96M	$3.55B	$1.07B
7 Day Performance	N/A	6.97%	1.70%	0.89%
1 Month Performance	N/A	4.03%	5.62%	6.56%
1 Year Performance	N/A	37.44%	34.42%	31.66%

NKGen Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NKGN NKGen Biotech	N/A	$0.06 flat	N/A	N/A	$7.84M	N/A	N/A	N/A
PLRZ Polyrizon	0.316 of 5 stars	$16.64 +4.7%	N/A	N/A	$31.12M	N/A	N/A	N/A	News Coverage Analyst Upgrade
SNTI Senti Biosciences	2.5988 of 5 stars	$1.00 +7.7%	$8.50 +753.4%	N/A	$30.93M	$22K	N/A	4
BCTX Briacell Therap	0.6068 of 5 stars	$4.14 -0.9%	N/A	N/A	$30.10M	N/A	N/A	8
AIXC Qualigen Therapeutics	0.0075 of 5 stars	$1.49 +1.7%	N/A	N/A	$30.06M	N/A	N/A	50	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NKGN) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NKGen Biotech (NKGN) Competitors

NKGN vs. PLRZ, SNTI, BCTX, AIXC, and BGM

How does NKGen Biotech compare to Polyrizon?

Summary

How does NKGen Biotech compare to Senti Biosciences?

Summary

How does NKGen Biotech compare to Briacell Therap?

Summary

How does NKGen Biotech compare to Qualigen Therapeutics?

Summary

How does NKGen Biotech compare to BGM Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKGN vs. The Competition

NKGen Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NKGen Biotech (NKGN) Competitors

NKGN vs. PLRZ, SNTI, BCTX, AIXC, and BGM

How does NKGen Biotech compare to Polyrizon?

Summary

How does NKGen Biotech compare to Senti Biosciences?

Summary

How does NKGen Biotech compare to Briacell Therap?

Summary

How does NKGen Biotech compare to Qualigen Therapeutics?

Summary

How does NKGen Biotech compare to BGM Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKGN vs. The Competition

NKGen Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools